Search - tctmd.com

Presenter: David R. Holmes, Brad Vazales, Louis A. Cannon, Elisabeth Stahle, Marie-Claude Morice, Michael J. Mack, Ted E. Feldman, A. Pieter Kappetein, Antonio Colombo, Keith D. Dawkins, Friedrich W. Mohr, Patrick W. Serruys

January 03, 2012

News Daily News

LIPSIA: No Rush for Treatment of High-Risk NSTEMI Patients

Leah Lawrence

December 08, 2011

Advertisement

El SLS es Efectivo contra la Reestenosis tanto Focal como Difusa del SLF

Randomized Trial of Optimal Treatment Strategies for In-Stent Restenosis After DES Implantation

SCIPIO: El Tratamiento con Células Madre Cardíacas Parece Prometedor a la luz de los Resultados Preliminares

Interdisciplinary Approach Needed for Cardiac Stem Cell Therapy to Move Forward

Meta-Analysis: Adjunctive Cilostazol Lowers Repeat Revascularization After PCI

Meta-Análisis: Cilostazol Adyuvante Reduce la Necesidad de Volver a Revascularizar tras una PCI

Paper Examines Differences Between Observational, Randomized PFO Closure Studies

Nuevo Análisis PLATO: Las dosis de Aspirina podrían Explicar los Resultados Discordantes de Norteamérica

New PLATO Analysis: Aspirin Dose May Explain Discordant North American Outcomes

COURAGE Substudy: Treat the Components, Not the Syndrome

Cerebrovascular Event Risk Highest in First 24 Hours After TAVR

Cardiac Stem Cell Therapy Safe, May Regenerate Heart Tissue

Abbott's Absolute Pro® Vascular Self-Expanding Stent System Receives FDA Approval for Treatment of Iliac Artery Disease

Meta-Analysis Questions Appropriateness of PCI in Stable CAD

Mitral Repair Can Augment Heart Function in CABG Patients

Induced Diuresis with Matched Hydration Reduces Contrast Nephropathy

Independent Data Safety Monitoring Board Recommends St. Jude Medical’s FAME II Clinical Trial Stop Enrollment Following Positive Interim Analysis

BRIDGE Published: Cangrelor Promising Option as Bridging Therapy

Four-year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients with Three-vessel Disease and/or Left Main Disease

LIPSIA: No Rush for Treatment of High-Risk NSTEMI Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content